Proactive Investors - Run By Investors For Investors

PreveCeutical says team has created 10-to-12 month plan aimed at concluding dual gene therapy R&D programme

The health sciences company noted that the plan was formulated at a recently held two-day intensive workshop which together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth
The R&D programme is intended to address the increasing prevalence of obesity and diabetes using smart siRNA
DNA strands

PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) said its research team at the University of Queensland has created a 10-to-12 month plan aimed at successfully concluding the current phase of its dual gene therapy research and development programme.

The health sciences company - which is developing innovative options for preventive and curative therapies utilizing organic and nature identical products - noted that the plan was formulated at a recently held two-day intensive workshop.

READ: PreveCeutical Medical set for due diligence trip on Penta 5 acquisition

That workshop brought together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth to collaborate on the R&D programme, which is intended to address the increasing prevalence of obesity and diabetes using smart siRNA and tissue targeted bio-responsive delivery systems.

The company said the programme aim is to demonstrate proof-of-concept in the delivery of smart siRNAs - small interfering Ribonucleic Acid, a class of double-stranded RNA molecules - and effective in-cell modulation of a key biomarker implicated in diabetes and obesity.

It pointed out that the primary objectives of the workshop were to share key data derived to-date from gene engineering, delivery system design and synthesis and their evaluation in cellular models of diabetes and obesity.

The group said the teams assessed and resolved potential assay bottlenecks, paving the way for high throughput screening of smart siRNA candidate libraries, which is anticipated to expedite the programme's progress.

Once the current phase of the program is complete, PreveCeutical added, it will move to the final phase where the safety and efficacy of the primary smart siRNA-delivery system constructs will be evaluated in preclinical models of diabetes and obesity.

View full PREV profile View Profile

PreveCeutical Medical Inc Timeline

Related Articles

pills
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
Pictured is the company's myLotus test
May 15 2019
Here we take a closer look at testing firm Concepta PLC (LON:CPT)
Sativa
April 02 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has made significant progress since it started trading on NEX.
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use